Page last updated: 2024-11-12

ko 143

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10322450
CHEMBL ID488910
CHEBI ID95026
SCHEMBL ID16645259
MeSH IDM0536778

Synonyms (33)

Synonym
ko 143 ,
ko-143
ko143
HY-10010
CHEMBL488910 ,
bdbm50305083
3-((3s,6s,12as)-6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydro-pyrazino[1'',2'':1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-butyl ester
3-((3s,6s)-6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydro-pyrazino[1'',2'':1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-butyl ester
tert-butyl 3-((3s,6s,12as)-6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)propanoate
AKOS016005202
BCP9000818
461054-93-3
(3s,6s,12as)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester
ko143 hydrate
CS-0298
S7043
BRD-K64642496-001-01-6
3-((3s,6s,12as)-6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-butylester
DTXSID30438079
EX-A745
SCHEMBL16645259
CHEBI:95026
(3s,6s,12as)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl) 1,4-dioxopyrazino [1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester
tert-butyl 3-[(2s,5s,8s)-14-methoxy-2-(2-methylpropyl)-4,7-dioxo-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraen-5-yl]propanoate
1,1-dimethylethyl (3s,6s,12as)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoate
mfcd11042273
(3s,6s,12as)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1,2:1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester
lsm-6260
Q27166789
gtpl10007
(3s,6s,12as)-1,2,3,4,6,7,12,12a-oct ahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyraz ino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester
A872285
AS-77372

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The design, synthesis, in vitro inhibitory potency, and pharmacokinetic (PK) profiles of Ko143 analogs are described."( Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Chmielecki, J; Chuang, BC; Guan, MY; Li, Y; Liao, M; Plesescu, M; Prakash, SR; Woo, J; Xia, CQ; Yang, JJ, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" These ABC drug efflux transporters extrude a wide range of xenotoxins from cells in intestine, liver, and other organs, thus affecting the bioavailability of many compounds."( Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Alvarez, AI; Jonker, JW; Merino, G; Molina, AJ; Pulido, MM; Schinkel, AH; Wagenaar, E, 2005
)
0.33
"54L/h/kg] and higher bioavailability [123%])."( Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Chmielecki, J; Chuang, BC; Guan, MY; Li, Y; Liao, M; Plesescu, M; Prakash, SR; Woo, J; Xia, CQ; Yang, JJ, 2016
)
0.43
" Multiple-target inhibitors of efflux transporter can be overcome the resistance and improve the oral bioavailability of chemotherapy drugs."( Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
beta-carbolinesAny pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives
tert-butyl esterA carboxylic ester resulting from the formal condensation of a carboxylic acid with tert-butanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)37.52700.00022.318510.0000AID1690374; AID1690381; AID1750901
Multidrug resistance-associated protein 1 Homo sapiens (human)IC50 (µMol)5.55000.00153.71109.6600AID1690376; AID1762378; AID653997
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)50.00002.41006.343310.0000AID370719
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)GI500.54030.27901.10521.9500AID1635791; AID1635792; AID1635793
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)0.18820.00401.966610.0000AID1057952; AID1057953; AID1065974; AID1167194; AID1206423; AID1228914; AID1303187; AID1335810; AID1335812; AID1356685; AID1381772; AID1447882; AID1479721; AID1479722; AID1501260; AID1501280; AID1525931; AID1532097; AID1553600; AID1625583; AID1635784; AID1635795; AID1635796; AID1690372; AID1723053; AID1723055; AID1873200; AID364887; AID370449; AID451987; AID451988; AID578759; AID578760; AID638477; AID638478; AID653991; AID678801; AID695336; AID734837; AID768689; AID768691
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Urokinase-type plasminogen activatorHomo sapiens (human)EC50 (µMol)0.01200.01200.01200.0120AID1129648
ATP-dependent translocase ABCB1Homo sapiens (human)EC50 (µMol)0.69080.01600.67863.1000AID1525922; AID1525944; AID1690379
Multidrug resistance-associated protein 1 Homo sapiens (human)EC50 (µMol)1.87501.70004.30289.8000AID1525921; AID1525943
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)EC50 (µMol)0.03980.00540.42203.2000AID1065985; AID1065986; AID1129629; AID1129648; AID1326798; AID1525919; AID1525920; AID1525942; AID1525951; AID1703310
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (65)

Processvia Protein(s)Taxonomy
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
leukotriene metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
response to xenobiotic stimulusMultidrug resistance-associated protein 1 Homo sapiens (human)
cobalamin transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid biosynthetic processMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to oxidative stressMultidrug resistance-associated protein 1 Homo sapiens (human)
heme catabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transportMultidrug resistance-associated protein 1 Homo sapiens (human)
phospholipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
positive regulation of inflammatory responseMultidrug resistance-associated protein 1 Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cell chemotaxisMultidrug resistance-associated protein 1 Homo sapiens (human)
transepithelial transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cyclic nucleotide transportMultidrug resistance-associated protein 1 Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 1 Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to amyloid-betaMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type vitamin B12 transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basal plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
lateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
extracellular exosomeMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (243)

Assay IDTitleYearJournalArticle
AID1832476Chemo-sensitizing activity against mitoxantrone-selected ABCG2-overexpressing human NCI-H460/MX20 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832434Chemo-sensitizing activity against human HEK293 cells assessed as mitoxantrone IC50 at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay (Rvb = 2.74 +/-0.69 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1356690Therapeutic index, ratio of GI50 for intrinsic cytotoxicity in MDCK2 cells overexpressing BCRP to IC50 for inhibition of c-terminal GFP-tagged human ABCG2 expressed in MDCK2 cells2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
AID578759Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID1635792Reversal of human ABCG2-mediated resistance to SN-38 in human ABCG2 expressed MDCK2 cells assessed as SN-38 GI50 at 0.1 uM after 72 hrs by MTT assay (Rvb SN-38 alone GI50 = 2.28 +/- 0.39 uM)2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID1129629Inhibition of ABCG2 (unknown origin) transfected in HEK293 cells assessed as inhibition of mitoxantrone efflux after 30 mins by flow cytometry relative to control2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
AID1690374Inhibition of ABCB1 in human KB-V1 cells using calcein-AM as substrate measured after 10 mins by fluorescence assay2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1447883Inhibition of recombinant human GFP-fused ABCG2 expressed in MDCK2 cells assessed as reduction in Hoechst 33342 efflux at 10 mM preincubated for 30 mins followed by Hoechst 33342 addition measured immediately at 60 sec time interval for 120 mins by fluore2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1904132Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as fold reduction in adriamycin IC50 at 5 uM measured after 48 hrs by MTT assay relative to adriamycin IC50 alone2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1832532Chemo-sensitizing activity against human HEK293 cells assessed as topotecan IC50 at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay (Rvb = 35.17 +/-8.65 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID370448Potentiation of ABCG2 positive topotecan-induced cytotoxicity in topotecan-resistant human MCF7 cells at 100 uM by chemosensitivity assay2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID1335812Inhibition of recombinant human GFP-fused ABCG2 expressed in MDCK2 cells assessed as reduction in pheophorbide A efflux preincubated for 30 mins followed by pheophorbide A addition measured after 2 hrs by flow cytometry2016European journal of medicinal chemistry, Nov-29, Volume: 124Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
AID1532106Therapeutic index, ratio of GI50 for cytotoxicity against MDCK2 cells harboring GFP-fused human ABCG2 to IC50 for inhibition of GFP-fused human ABCG2 expressed in MDCK2 cells2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1832519Chemo-sensitizing activity against becatecarin-selected ABCG2-overexpressing human A549/Bec150 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1557150Reversal of ABCG2 482-T7 mutant (unknown origin) expressed in HEK293 cells-mediated multidrug resistance assessed as potentiation of mitoxantrone-induced cytotoxicity at 5 uM pretreated for 2 hrs followed by mitoxantrone addition and measured after 44 hrs2019European journal of medicinal chemistry, Oct-01, Volume: 179Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
AID1303207Therapeutic ratio of GI50 for MDCK2 cells expressing human C-terminal GFP-tagged ABCG2 to IC50 for human C-terminal GFP-tagged ABCG2 expressed in MDCK2 cells2016European journal of medicinal chemistry, Jul-19, Volume: 117The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID1525932Inhibition of BCRP (unknown origin) transfected in human HEK293/R2 cells assessed as fold reduction in topotecan IC50 at 1 uM relative to topotecan IC502019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1525918Cytotoxicity against human L929 cells assessed as reduction in cell viability2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1447882Inhibition of recombinant human GFP-fused ABCG2 expressed in MDCK2 cells assessed as reduction in Hoechst 33342 efflux preincubated for 30 mins followed by Hoechst 33342 addition measured immediately at 60 sec time interval for 120 mins by fluorescence as2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1335811Inhibition of recombinant human GFP-fused ABCG2 expressed in MDCK2 cells assessed as reduction in pheophorbide A efflux at 10 uM preincubated for 30 mins followed by pheophorbide A addition measured after 2 hrs by flow cytometry relative to XR95772016European journal of medicinal chemistry, Nov-29, Volume: 124Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
AID1268163AUC (0 to 24 hrs) in Sprague-Dawley rat at 2 mg/kg, iv2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
AID1832541Chemo-sensitizing activity against ABCG2-overexpressing human HEK293/482R cells assessed as SN-38 IC50 at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay (Rvb = 239.91 +/-25 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1625584Inhibition of c-terminal GFP-tagged human ABCG2 expressed in MDCK2 cells preincubated for 30 mins before Pheophorbide A addition by Pheophorbide A assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1356686Inhibition of ABCB1 in human A2780adr cells at 10 uM preincubated for 30 mins before calcein AM addition by calcein AM assay relative to cyclosporine A2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
AID1904174Effect on BCRP expression in dog MDCK-II-BCRP cells at 5 uM measured by Western blot analysis2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1625590Intrinsic cytotoxicity against parental MDCK2 cells incubated for 72 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1356689Intrinsic cytotoxicity in parental MDCK2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
AID1065985Inhibition of ABCG2 (unknown origin)-mediated mitoxantrone efflux expressed in HEK293 cells after 30 mins by flow cytometric analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
AID1832516Chemo-sensitizing activity against human A549 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1268165Clearance in Sprague-Dawley rat at 2 mg/kg, iv2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
AID1525929Cytotoxicity against human L929 cells assessed as topotecan IC50 at 1 uM (Rvb = 1168 +/- 109 nM)2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1832538Chemo-sensitizing activity against human HEK293 cells assessed as SN-38 IC50 at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay (Rvb = 2.78 +/-0.58 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1268174Oral bioavailability in Sprague-Dawley rat at 50 mg/kg2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
AID1303212Potentiation of SN-38-induced cytotoxicity in MDCK2 cells assessed as decrease in cell viability at 0.01 to 0.1 uM after 72 hrs by MTT assay2016European journal of medicinal chemistry, Jul-19, Volume: 117The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID1303206Cytotoxicity against MDCK2 cells expressing human C-terminal GFP-tagged ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Jul-19, Volume: 117The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID1335808Non-competitive inhibition of recombinant human GFP-fused ABCG2 expressed in MDCK2 cells assessed as reduction in pheophorbide A efflux at 0.0178 to 0.1 uM preincubated for 30 mins followed by addition of varying levels of pheophorbide A by Lineweaver-Bur2016European journal of medicinal chemistry, Nov-29, Volume: 124Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
AID1532105Growth inhibition of MDCK2 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1750897Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay
AID695336Inhibition of human BCRP expressed in MDCK2 cells preincubated for 30 mins prior to Hoechst 33342 addition measured every 60 secs up to 120 mins by Hoechst 33342 accumulation assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
4-Substituted-2-phenylquinazolines as inhibitors of BCRP.
AID1525943Inhibition of MRP1 (unknown origin) expressed in human 2008/MRP1 cells assessed as potentiation of mitoxantrone-induced cytotoxicity after 5 days by MTS/PMS assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1303189Induction of vanadate-sensitive ATPase activity of recombinant human ABCG2 expressed in baculovirus infected Sf9 cell membrane assessed as increase in inorganic phosphate production at 1 uM after 20 mins by colorimetry2016European journal of medicinal chemistry, Jul-19, Volume: 117The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID1635779Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID1228913Modulation of MRP1 (unknown origin) transfected in human 2008/MRP1 cells assessed as potentiation of doxorubicin-induced cytotoxicity measured as doxorubicin IC50 at 1 uM after 5 days by MTS assay relative to doxorubicin alone treated cell2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID370719Inhibition of ABCC2 overexpressed in MDCK cells at 100 uM by flow cytometric-based chloromethylfluorescein-diacetate accumulation assay2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID679513TP_TRANSPORTER: transepithelial transport of PhIP (basal to apical) in BCRP-expressing MDCKII cells2005Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 33, Issue:5
Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
AID734837Inhibition of ABCG2 in human MCF7/Topo cells after 2 hrs by Hoechst 33342 microplate assay2013ACS medicinal chemistry letters, Apr-11, Volume: 4, Issue:4
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.
AID1690385Cytotoxicity against human MCF7/Topo cells assessed as reduction in cell viability at 10 uM by crystal violet staining based assay2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1525921Inhibition of MRP1 (unknown origin) expressed in human 2008/MRP1 assessed as reversal of doxorubicin resistance after 5 days by MTS/PMS assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1525920Inhibition of BCRP in human MCF7/MX100 cells assessed as reversal of topotecan resistance after 5 days by MTS/PMS assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID653999Cytotoxicity against human HEK293 cells transfected with ABCG2 after 72 hrs by MTT assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
AID1832455Chemo-sensitizing activity against human NCI-H460 cells assessed as topotecan IC50 at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay (Rvb = 279.69 +/-31.94 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1303211Inhibition of human C-terminal GFP-tagged ABCG2 expressed in MDCK2 cells assessed as SN-38-induced cytotoxicity by measuring cell viability at 0.01 to 0.1 uM after 72 hrs by MTT assay2016European journal of medicinal chemistry, Jul-19, Volume: 117The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID1832461Chemo-sensitizing activity against human NCI-H460 cells assessed as SN-38 IC50 at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay (Rvb = 128.27 +/-22.6 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832535Chemo-sensitizing activity against ABCG2-overexpressing human HEK293/482R cells assessed as topotecan IC50 at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay (Rvb = 558.68 +/-81.31 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID364887Inhibition of ABCG2 in human mitoxantrone-resistant MCF7 cells by Hoechst 33342 assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID1065987Inhibition of ABCG2-mediated mitoxantrone efflux in mitoxantrone-selected human H460 cells at 5 to 10 uM after 30 mins by flow cytometric analysis relative to control2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
AID1326802Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
AID1525925Selectivity index, ratio of EC50 for inhibition of MRP1 (unknown origin) expressed in 2008/MRP1 assessed as reversal of doxorubicin resistance to EC50 for inhibition of BCRP (unknown origin) transfected in HEK293/R2 cells assessed as reversal of topotecan2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1525944Inhibition of P-gp (unknown origin) expressed in human LCC6MDR cells assessed as potentiation of mitoxantrone-induced cytotoxicity after 5 days by MTS/PMS assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1690379Activation of ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1062331Modulation of BCRP (unknown origin) transfected in human HEK293/R2 cells assessed as potentiation of topotecan-induced cytotoxicity at 1 uM after 5 days by MTS assay relative to untreated control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Structure-activity relationship study of permethyl ningalin B analogues as P-glycoprotein chemosensitizers.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1832464Chemo-sensitizing activity against mitoxantrone-selected ABCG2-overexpressing human NCI-H460/MX20 cells assessed as SN-38 IC50 at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay (Rvb = 4.33 +/-1.18 microM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1635778Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID370449Inhibition of ABCG2 overexpressed in human MCF7/Topo cells by flow cytometric-based mitoxantrone efflux assay2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID1356702Non-competitive inhibition of c-terminal GFP-tagged human ABCG2 expressed in MDCK2 cells preincubated for 30 mins before Hoechst 33342 addition by Hoechst 33342 accumulation assay based Lineweaver-Burk plot analysis2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
AID1750929Inhibition of BCRP-mediated multidrug resistance in MDCK-II cells assessed as mitoxantrone accumulation at 0.1 to 5 uM pretreated 1 hr followed by treated with mitoxantrone measured after 180 mins by flow cytometry
AID654001Therapeutic index, ratio of GI50 for human HEK293 cells transfected with ABCG2 to IC50 for ABCG2-mediated mitoxantrone efflux in HEK293 cells2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
AID1832488Chemo-sensitizing activity against becatecarin-selected ABCG2-overexpressing human A549/Bec150 cells assessed as mitoxantrone IC50 at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay (Rvb = 552.97 +/-106.74 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1303205Cytotoxicity against MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Jul-19, Volume: 117The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID370717Inhibition of ABCB1 overexpressed in human KBv1 cells at 10 uM by flow cytometric-based calcein-AM efflux assay2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID1525942Inhibition of BCRP (unknown origin) expressed in human HEK293/R2 cells assessed as potentiation of mitoxantrone-induced cytotoxicity after 5 days by MTS/PMS assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1635794Reversal of human ABCG2-mediated resistance to SN-38 in human ABCG2 expressed MDCK2 cells assessed as reduction in SN-38 GI50 after 72 hrs by MTT assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID679626TP_TRANSPORTER: inhibition of ATPase activity in BCRP-expressing Sf9 cells2004Molecular pharmacology, Jun, Volume: 65, Issue:6
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
AID1770092Inhibition of ABCG2 (unknown origin) expressed in MDCK-II cells assessed as reduction in pheophorbide A accumulation at 0.2 uM pre-incubated for 30 mins followed by wash out and once again compound addition for 45 mins by flow cytometry analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.
AID1532097Inhibition of GFP-fused human ABCG2 expressed in MDCK2 cells assessed as Hoechst 33342 accumulation preincubated for 30 mins followed by Hoechst 33342 addition by fluorescence assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1525923Cytotoxicity against mouse 3T3 cells assessed as reduction in cell viability2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID451988Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
AID1525945Inhibition of BCRP (unknown origin) expressed in human HEK293/R2 cells assessed as increase in intracellular topotecan accumulation by measuring fold change at 1 uM after 120 mins in presence of topotecan by flow cytometry analysis relative to control2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1690373Inhibition of ABCG2 in topotecan-cultured human MCF7 cells using Hoechst 33342 as substrate measured after 2 hrs by fluorescence assay relative to FTC2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1723053Inhibition of human ABCG2 expressed in MDCK2 cells co-expressing GFP preincubated for 30 mins followed by Hoechst 33342 addition and measured every 60 sec for 120 mins by fluorescence assay
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1065974Inhibition of human ABCG2 expressed in Sf9 insect cell membranes assessed as inhibition of quercetin-stimulated ATPase activity after 30 mins by colorimetric analysis in presence of sodium orthovanadate2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
AID1635796Inhibition of human ABCG2 expressed in baculovirus infected Sf9 cell membrane assessed as inhibition of vanadate sensitive quercetin-stimulated ATPase activity after 20 mins by colorimetric method2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID1381772Inhibition of C-terminal GFP-fused human ABCG2 expressed in MDCK2 cells preincubated for 30 mins followed by Hoechst 33342 addition and measured every 60 secs for 120 mins by Hoechst 33342 accumulation assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.
AID1703309Inhibition of ABCG2 (unknown origin) in HEK293 cells assessed as maximal inhibition of mitoxantrone efflux at 1 uM by fluorescence based flow cytometry relative to control2020European journal of medicinal chemistry, Sep-15, Volume: 202Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
AID1525950Inhibition of vanadate sensitive BCRP ATPase activity in human S1-M1-80 cell membranes preincubated for 30 mins followed by ATP addition and measured after 1 hr by colorimetric assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1381774Inhibition of C-terminal GFP-fused human ABCG2 expressed in MDCK2 cells up to 10 uM preincubated for 30 mins followed by Hoechst 33342 addition and measured every 60 secs for 120 mins by Hoechst 33342 accumulation assay relative to XR95772018European journal of medicinal chemistry, Feb-25, Volume: 146Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors.
AID666858Reversal of BCRP-mediated drug resistant in human MCF7-MX100 cells assessed as potentiation of topotecan-induced cytotoxicity at 1 uM after 5 days by MTS assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
AID1635795Inhibition of human ABCG2 expressed in baculovirus infected Sf9 cell membrane assessed as inhibition of vanadate sensitive basal ATPase activity after 20 mins by colorimetric method2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID679679TP_TRANSPORTER: transepithelial transport of PhIP (basal to apical) in Bcrp1-expressing MDCKII cells2005Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 33, Issue:5
Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
AID1832467Chemo-sensitizing activity against human NCI-H460 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1228914Modulation of BCRP (unknown origin) transfected in human HEK293/R2 cells assessed as potentiation of topotecan-induced cytotoxicity measured as topotecan IC50 at 1 uM after 5 days by MTS assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID714424Inhibition of BCRP-mediated topotecan resistance in human HEK293/R2 cells assessed as fold decrease in topotecan IC50 for cytotoxic activity at 0.5 uM after 5 days by MTS assay relative to parental cell2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID1832522Chemo-sensitizing activity against human A549 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832544Chemo-sensitizing activity against human HEK293 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of mitoxatrone by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1447888Cytotoxicity against ABCG2 over-expressing MDCK2 cells assessed as cell growth inhibition after 72 hrs by MTT assay2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1832507Chemo-sensitizing activity against becatecarin-selected ABCG2-overexpressing human A549/Bec150 cells assessed as SN-38 IC50 at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay (Rvb = 1625.4 +/-413.42 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1723054Inhibition of human ABCG2 expressed in MDCK2 cells co-expressing GFP preincubated for 30 mins followed by Hoechst 33342 addition and measured every 60 sec for 120 mins by fluorescence assay relative to control
AID1368941Inhibition of BCRP (unknown origin) expressed in HEK293 cells assessed as reduction in mitoxantrone efflux at 1 uM incubated for 30 mins by flow cytometric analysis relative to control2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Monoterpene indole alkaloid azine derivatives as MDR reversal agents.
AID1635791Reversal of human ABCG2-mediated resistance to SN-38 in human ABCG2 expressed MDCK2 cells assessed as SN-38 GI50 at 0.01 uM after 72 hrs by MTT assay (Rvb SN-38 alone GI50 = 2.28 +/- 0.39 uM)2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID1723056Inhibition of human ABCG2 expressed in MDCK2 cells co-expressing GFP preincubated for 15 mins followed by pheophorbideA addition and measured after 2 hrs by flow cytometric analysis relative to control
AID1447889Cytotoxicity against MDCK2 cells assessed as cell growth inhibition after 72 hrs by MTT assay2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1703310Inhibition of ABCG2 (unknown origin) in HEK293 cells assessed as maximal inhibition of mitoxantrone efflux by fluorescence based flow cytometry2020European journal of medicinal chemistry, Sep-15, Volume: 202Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
AID1690383Stabilization of human ABCG2 assessed as melting temperature at 10 uM measured after 10 mins by size-exclusion chromatography-based thermostability assay (Rvb = 53.3 +/- 0.3 degC)2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1557148Reversal of ABCG2 (unknown origin) expressed in HEK293 cells-mediated multidrug resistance assessed as potentiation of mitoxantrone-induced cytotoxicity at 5 uM pretreated for 2 hrs followed by mitoxantrone addition and measured after 44 hrs by MTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
AID1129648Inhibition of ABCG2 (unknown origin) transfected in HEK293 cells assessed as inhibition of mitoxantrone efflux at 5 uM after 30 mins in presence of 0.1 uM (2E,2'E)-1,1'-(1,4-Phenylene)bis(3-(2,6-dimethoxyphenyl)-prop-2-en-1-one) by flow cytometry2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
AID1762378Inhibition of ABCC1 mediated etoposide resistant in human 2008 cells
AID734839Inhibition of ABCB1 in human KBV1 cells up to 100 uM after 10 mins by Calcein-AM microplate assay2013ACS medicinal chemistry letters, Apr-11, Volume: 4, Issue:4
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.
AID653997Inhibition of MRP12012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
AID451987Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
AID1213373Inhibition of P-gp-mediated [3H]-digoxin transport in human Caco2 cells at 3 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
AID638477Inhibition of BCRP in human MCF7/MX cells assessed as Hoechst 33342 accumulation preincubated for 30 mins by Fluorometry2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
AID1532115Non-competitive inhibition of GFP-fused human ABCG2 expressed in MDCK2 cells using varying levels of Hoechst 33342 as substrate preincubated for 30 mins followed by Hoechst 33342 addition by Cornish-Bowden plot analysis2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1557138Inhibition of ABCG2-mediated mitoxantrone efflux in human NCI-H460/MX20 cells assessed as increase in accumulation of [3H]MX at 5 uM incubated for 2 hrs followed by [3H]MX addition further incubated for 2 hrs by liquid scintillation counter relative to co2019European journal of medicinal chemistry, Oct-01, Volume: 179Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
AID1356708Binding affinity to ABCG2 in human PLB-985 cells assessed as 5D3 labelling level at 10 uM by 5D3 antibody binding assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
AID1557147Metabolic stability in human liver microsomes assessed as compound remaining at 100 uM incubated for 1 hr by HPLC analysis2019European journal of medicinal chemistry, Oct-01, Volume: 179Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
AID1501267Cytotoxicity against MDCK2 cells assessed as cell growth inhibition after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
AID1832473Chemo-sensitizing activity against human NCI-H460 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID678801TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells2004Molecular pharmacology, Jun, Volume: 65, Issue:6
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
AID1553600Inhibition of ABCG2 (unknown origin) expressed in MDCK2 cells co-expressing BCRP (unknown origin) assessed as effect on pheophorbide A accumulation pre-incubated for 20 mins followed by pheophorbide A addition and measured after 120 mins by flow cytometri2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach.
AID1832482Chemo-sensitizing activity against mitoxantrone-selected ABCG2-overexpressing human NCI-H460/MX20 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1447890Therapeutic index, ratio of GI50 for ABCG2 over-expressing MDCK2 cells to IC50 for recombinant human GFP-fused ABCG2 expressed in MDCK2 cells2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1479722Inhibition of ABCG2 in human PLB-985 cells assessed as increase in accumulation of Hoechst 33342 preincubated for 30 mins followed by Hoechst 33342 addition measured every 60 secs for 120 mins by fluorescence assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
AID1525922Inhibition of P-gp (unknown origin) expressed in human LCC6MDR cells assessed as reversal of paclitaxel resistance after 5 days by MTS/PMS assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1525924Cytotoxicity against human HFF1 cells assessed as reduction in cell viability2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID768689Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID1501260Inhibition of human GFP-fused ABCG2 expressed in MDCK2 cells assessed as reduction in Hoechst 33342 efflux preincubated for 30 mins followed by Hoechst 33342 addition measured at 60 secs interval up to 120 mins by fluorescence assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
AID1832491Chemo-sensitizing activity against human A549 cells assessed as topotecan IC50 at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay (Rvb =555.44 +/-125.7 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID768691Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID1832452Chemo-sensitizing activity against mitoxantrone-selected ABCG2-overexpressing human NCI-H460/MX20 cells assessed as mitoxantrone IC50 at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay (Rvb = 963.32 +/-120.89 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1557113Reversal of ABCG2-mediated multidrug resistance in human S1-M1-80 cells assessed as potentiation of doxorubicin-induced cytotoxicity at 5 uM pretreated with compound for 2 hrs followed by doxorubicin challenge for 44 hrs by MTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID370447Cytotoxicity against ABCG2 positive topotecan-resistant human MCF7 cells up to 500 uM by chemosensitivity assay2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID1268170Inhibition of P-gp transporter in human Caco2 cells using [3H]-digoxin as substrate measured at 30 to 120 mins by microplate scintillation and luminescence counting analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
AID1525927Selectivity index, ratio of EC50 for inhibition of P-gp (unknown origin) expressed in LCC6MDR cells assessed as reversal of paclitaxel resistance to EC50 for inhibition of BCRP (unknown origin) transfected in HEK293/R2 cells assessed as reversal of topote2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1228912Modulation of MRP1 (unknown origin) transfected in human 2008/MRP1 cells assessed as potentiation of doxorubicin-induced cytotoxicity measured as doxorubicin IC50 at 1 uM after 5 days by MTS assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID1268164AUC (0 to 24 hrs) in Sprague-Dawley rat at 50 mg/kg, po2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
AID1723055Inhibition of human ABCG2 expressed in MDCK2 cells co-expressing GFP preincubated for 15 mins followed by pheophorbideA addition and measured after 2 hrs by flow cytometric analysis
AID1832458Chemo-sensitizing activity against mitoxantrone-selected ABCG2-overexpressing human NCI-H460/MX20 cells assessed as topotecan IC50 at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay (Rvb = 3262.6 +/-811.81 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1832547Chemo-sensitizing activity against ABCG2-overexpressing human HEK293/482R cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of mitoxatrone by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1167193Inhibition of ABCG2 (unknown origin) expressed in HEK293 cells assessed as reduction in mitoxantrone efflux at 10 uM after 30 mins by FACS method2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
AID1750903Reversal of BCRP-mediated multidrug resistance in MDCK-II cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by measuring adriamycin IC50 after 48 hrs by MTT assay
AID1690376Inhibition of human ABCC1 transfected in MDCK2-MRP1 cells using calcein-AM as substrate measured after 1 hr by fluorescence assay2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1625583Inhibition of c-terminal GFP-tagged human ABCG2 expressed in MDCK2 cells preincubated for 30 mins before Hoechst 33342 addition by Hoechst 33342 accumulation assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1057953Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
AID1635793Reversal of human ABCG2-mediated resistance to SN-38 in human ABCG2 expressed MDCK2 cells assessed as SN-38 GI50 at 1 uM after 72 hrs by MTT assay (Rvb SN-38 alone GI50 = 2.28 +/- 0.39 uM)2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID1690381Inhibition of sulfasalazine-stimulated ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1525919Inhibition of BCRP (unknown origin) transfected in HEK293/R2 cells assessed as reversal of topotecan resistance after 5 days by MTS/PMS assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1832501Chemo-sensitizing activity against becatecarin-selected ABCG2-overexpressing human A549/Bec150 cells assessed as topotecan IC50 at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay (Rvb = 1162.92 +/-250.73 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1904133Reversal of BCRP-mediated multidrug resistance in dog MDCK-II-BCRP cells assessed as fold reduction in mitoxantrone IC50 at 5 uM measured after 48 hrs by MTT assay relative to mitoxantrone IC50 alone2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1065984Inhibition of ABCG2 (unknown origin)-mediated mitoxantrone efflux expressed in HEK293 cells at 5 to 10 uM after 30 mins by flow cytometric analysis relative to control2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
AID1525931Inhibition of BCRP (unknown origin) transfected in human HEK293/R2 cells assessed as potentiation of topotecan-induced cytotoxicity measured as topotecan IC50 at 1 uM (Rvb = 531.5 +/- 180 nM)2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1525930Cytotoxicity against human L929 cells assessed as fold reduction in topotecan IC50 at 1 uM relative to topotecan IC502019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1532114Non-competitive inhibition of GFP-fused human ABCG2 expressed in MDCK2 cells up to 3160 nM using varying levels of Hoechst 33342 as substrate preincubated for 30 mins followed by Hoechst 33342 addition by Lineweaver-Burk plot analysis2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1904128Cytotoxicity against dog MDCK cells after 48 hrs by MTT assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID734836Inhibition of ABCG2 in human MCF7/Topo cells at 70 to 100 uM after 2 hrs by Hoechst 33342 microplate assay relative to 10 uM fumitremorgin2013ACS medicinal chemistry letters, Apr-11, Volume: 4, Issue:4
Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.
AID1690384Cytotoxicity against human MCF7/Topo cells assessed as reduction in cell viability up to 3 uM by crystal violet staining based assay2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1268173Cmax in Sprague-Dawley rat at 50 mg/kg, po2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
AID1690382Inhibition of sulfasalazine-stimulated ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay relative to FTC2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1750899Cytotoxicity against MDCK-II cells incubated for 48 hrs by MTT assay
AID1501278Activation of ABCG2 ATPase activity (unknown origin) expressed in baculovirus infected high5 cell membranes assessed as enzyme activity after 20 mins by ascorbic acid ammonia molybdate reaction based colorimetric assay relative to control2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
AID1635798Inhibition of human ABCG2 expressed in baculovirus infected Sf9 cell membrane assessed as inhibition of vanadate sensitive ATPase activity at 1 uM after 20 mins by colorimetric method2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID1832559Chemo-sensitizing activity against ABCG2-overexpressing human HEK293/482R cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1335810Inhibition of recombinant human GFP-fused ABCG2 expressed in MDCK2 cells assessed as reduction in Hoechst 33342 efflux preincubated for 30 mins followed by Hoechst 33342 addition measured immediately at 60 sec time interval for 120 mins by fluorescence as2016European journal of medicinal chemistry, Nov-29, Volume: 124Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
AID1268158Half-life in Sprague-Dawley rat at 2 mg/kg, iv2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
AID1335813Competitive inhibition of recombinant human GFP-fused ABCG2 expressed in MDCK2 cells assessed as reduction in Hoechst 33342 efflux at 0.01 to 0.1 uM preincubated for 30 mins followed by addition of varying levels of Hoechst 33342 by Lineweaver-Burk plot a2016European journal of medicinal chemistry, Nov-29, Volume: 124Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
AID1501268Therapeutic ratio of GI50 for MDCK2 cells harboring human ABCG2 to IC50 for human GFP-fused ABCG2 expressed in MDCK2 cells2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
AID1326803Therapeutic ratio of IG50 for human HEK293 cells to EC50 for ABCG2 (unknown origin) expressed in HEK293 cells2016European journal of medicinal chemistry, Oct-21, Volume: 122New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
AID1832485Chemo-sensitizing activity against human A549 cells assessed as mitoxantrone IC50 at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay (Rvb = 82.47 +/-24.25 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1690378Inhibition of human ABCC1 transfected in MDCK2-MRP1 cells using calcein-AM as substrate measured after 1 hr by fluorescence assay relative to reversan2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1065977Inhibition of human ABCG2 ATPase activity expressed in Sf9 insect cell membranes at 2 uM after 30 mins by colorimetric analysis relative to basal control in presence of sodium orthovanadate2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
AID666857Reversal of BCRP-mediated drug resistant in human HEK293/R2 cells assessed as potentiation of topotecan-induced cytotoxicity at 1 uM after 5 days by MTS assay2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
AID1832525Chemo-sensitizing activity against becatecarin-selected ABCG2-overexpressing human A549/Bec150 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1690372Inhibition of ABCG2 in topotecan-cultured human MCF7 cells using Hoechst 33342 as substrate measured after 2 hrs by fluorescence assay2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID638478Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation preincubated for 30 mins by fluorimetry2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
AID1213374Inhibition of BCRP-mediated [3H]estrone-3-sulfate transport in human Caco2 cells at 3 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4
Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
AID1832449Chemo-sensitizing activity against human NCI-H460 cells assessed as mitoxantrone IC50 at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay (Rvb = 20.7 +/-6.32 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1635784Inhibition of human ABCG2 expressed in MDCK2 cells assessed as reduction in Hoechst 33342 efflux pre-incubated for 30 mins before Hoechst 33342 addition and measured for 120 mins by microplate reader analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID1532104Growth inhibition of MDCK2 cells harboring GFP-fused human ABCG2 after 72 hrs by MTT assay2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1525926Selectivity index, ratio of EC50 for inhibition of MRP1 (unknown origin) expressed in 2008/MRP1 assessed as reversal of doxorubicin resistance to Inhibition of BCRP in MCF7/MX100 cells assessed as reversal of topotecan resistance2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID364885Inhibition of P-gp in human adriamycin-resistant A2780 cells up to 30 uM by Hoechst 33342 assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID1625589Intrinsic cytotoxicity against MDCK2 cells over-expressing human ABCG2 incubated for 72 hrs by MTT assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID653991Inhibition of ABCG2-mediated mitoxantrone efflux in HEK293 cells by flow cytometry2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
AID1167196Intrinsic cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
AID1750904Reversal of BCRP-mediated multidrug resistance in MDCK-II cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM after 48 hrs by MTT assay relative to control
AID1832553Chemo-sensitizing activity against ABCG2-overexpressing human HEK293 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1904130Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by measuring adriamycin IC50 after 48 hrs by MTT assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1557149Reversal of ABCG2 482-G2 mutant (unknown origin) expressed in HEK293 cells-mediated multidrug resistance assessed as potentiation of mitoxantrone-induced cytotoxicity at 5 uM pretreated for 2 hrs followed by mitoxantrone addition and measured after 44 hrs2019European journal of medicinal chemistry, Oct-01, Volume: 179Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
AID1501280Inhibition of ABCG2 ATPase activity (unknown origin) expressed in baculovirus infected high5 cell membranes after 20 mins by ascorbic acid ammonia molybdate reaction based colorimetric assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
AID1268172Tmax in Sprague-Dawley rat at 50 mg/kg, po2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
AID1525928Selectivity index, ratio of EC50 for inhibition of P-gp (unknown origin) expressed in LCC6MDR cells assessed as reversal of paclitaxel resistance to Inhibition of BCRP in MCF7/MX100 cells assessed as reversal of topotecan resistance2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1832556Chemo-sensitizing activity against human HEK293 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1750902Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by after 48 hrs by MTT assay relative to control
AID1832510Chemo-sensitizing activity against human A549 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1690386Inhibition of ABCG2 in human MCF7/Topo cells assessed as potentiation of topotecan-induced cytotoxicity at non-toxic concentration by crystal violet staining based assay2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1479725Cytotoxicity against MDCK2 cells expressing human BCRP assessed as decrease in cell viability after 72 hrs by MTT assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
AID1356685Inhibition of c-terminal GFP-tagged human ABCG2 expressed in MDCK2 cells preincubated for 30 mins before Hoechst 33342 addition by Hoechst 33342 accumulation assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
AID1832504Chemo-sensitizing activity against human A549 cells assessed as SN-38 IC50 at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay (Rvb = 376.13 +/-60.17 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1649250Reversal of ABCG2-mediated mitoxantrone resistance in human NCI-H460/MX20 cells assessed as potentiation of mitoxantrone-induced cytotoxicity by measuring change in mitoxantrone IC50 at 10 uM incubated for 48 hrs by SRB assay relative to mitoxantrone IC502020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue.
AID1228915Modulation of BCRP (unknown origin) transfected in human HEK293/R2 cells assessed as potentiation of topotecan-induced cytotoxicity measured as topotecan IC50 at 1 uM after 5 days by MTS assay relative to topotecan alone treated cell2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID1832513Chemo-sensitizing activity against becatecarin-selected ABCG2-overexpressing human A549/Bec150 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID653996Selectivity ratio of IC50 for P-glycoprotein/ABCB1 to IC50 for ABCG22012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
AID1832479Chemo-sensitizing activity against human NCI-H460 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of SN-38 by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1206423Inhibition of GFP-tagged human BCRP expressed in MDCK2 cells pre-incubated for 30 mins followed by Hoechst 33342 addition and further incubated for 120 mins by Hoechst 33342 accumulation assay2015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
AID1873200Inhibition of human ABCG2 expressed in dog MDCK-II-BCRP cells mediated pheophorbide A efflux preincubated with PhA followed by compound addition and measured after 60 mins by flow cytometry2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1690375Inhibition of ABCB1 in human KB-V1 cells using calcein-AM as substrate measured after 10 mins by fluorescence assay relative to tariquidar2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1557114Reversal of ABCG2-mediated multidrug resistance in human S1-M1-80 cells assessed as potentiation of mitoxantrone-induced cytotoxicity at 5 uM pretreated with compound for 2 hrs followed by mitoxantrone challenge for 44 hrs by MTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1625591Therapeutic index, ratio of GI50 for intrinsic cytotoxicity against MDCK2 cells over-expressing human ABCG2 top IC50 for inhibition of c-terminal GFP-tagged human ABCG2 expressed in MDCK2 cells2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1206425Inhibition of GFP-tagged human BCRP expressed in MDCK2 cells pre-incubated for 30 mins followed by Hoechst 33342 addition and further incubated for 120 mins by Hoechst 33342 accumulation assay relative to XR95772015Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
AID1635783Inhibition of human ABCG2 expressed in MDCK2 cells assessed as reduction in pheophorbide A efflux pre-incubated for 30 mins before Hoechst 33342 addition and measured for 120 mins by flow cytometry2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID1326798Inhibition of ABCG2 (unknown origin) expressed in HEK293 cells assessed as reduction in mitoxantrone efflux after 30 mins by flow cytometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
AID1067619Inhibition of BCRP (unknown origin) expressed in mouse NIH/3T3 cells assessed as inhibition of mitoxatrone efflux at 2 uM after 1 hr by FACS analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease.
AID1479721Inhibition of human ABCG2 expressed in MDCK2 cells assessed as increase in accumulation of Hoechst 33342 preincubated for 30 mins followed by Hoechst 33342 addition measured every 60 secs for 120 mins by fluorescence assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
AID1057952Inhibition of human BCRP expressed in MDCK2 cells assessed as pheophorbide A accumulation treated 30 mins before pheophorbide A addition measured up to 120 mins by flow cytometry2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
AID1832550Chemo-sensitizing activity against human HEK293 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of topotecan by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1065986Inhibition of ABCG2-mediated mitoxantrone efflux in mitoxantrone-selected human H460 cells after 30 mins by flow cytometric analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.
AID1479743Induction of conformational changes in ABCG2 in human PLB-985 cells assessed as 5D3 antibody binding to protein at 10 uM preincubated for 5 mins followed by antibody addition measured after 30 mins by flow cytometric method relative to control2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
AID1750898Cytotoxicity against P-gp overexpressing human K562/A02 cells incubated for 48 hrs by MTT assay
AID1750901Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by measuring adriamycin IC50 after 48 hrs by MTT assay
AID1501266Cytotoxicity against MDCK2 cells harboring human ABCG2 assessed as cell growth inhibition after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
AID1635797Ratio of IC50 for human ABCG2 expressed in baculovirus infected Sf9 cell membrane assessed as inhibition of vanadate sensitive quercetin-stimulated ATPase activity to IC50 for human ABCG2 expressed in baculovirus infected Sf9 cell membrane assessed as inh2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID1335809Inhibition of recombinant human GFP-fused ABCG2 expressed in MDCK2 cells assessed as reduction in Hoechst 33342 efflux at 10 uM preincubated for 30 mins followed by Hoechst 33342 addition measured immediately at 60 sec time interval for 120 mins by fluore2016European journal of medicinal chemistry, Nov-29, Volume: 124Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
AID370450Inhibition of ABCG2 over-expressed in human MCF7/Topo cells at 7 to 10 uM by flow cytometric-based mitoxantrone efflux assay relative to fumitremorgin C2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
AID1832529Chemo-sensitizing activity against ABCG2-overexpressing human HEK293/482R cells cells assessed as mitoxantrone IC50 at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay (Rvb = 99.55 +/-7.35 nM)2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1129643Inhibition of human ABCG2 transfected in Sf9 insect cells assessed as inhibition of basal ATPase activity in absence of substrate drug after 30 mins by colorimetry2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
AID1356687Inhibition of ABCC1 in human H69AR cells at 10 uM preincubated for 30 mins before calcein AM addition by calcein AM assay relative to cyclosporine A2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
AID1904131Reversal of BCRP-mediated multidrug resistance in dog MDCK-II-BCRP cells assessed as potentiation of mitoxantrone-induced cytotoxicity at 5 uM by measuring mitoxantrone IC50 after 48 hrs by MTT assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID1750900Cytotoxicity against BCRP-overexpressing MDCK-II cells incubated for 48 hrs by MTT assay
AID1303190Inhibition of vanadate-sensitive ATPase activity of recombinant human ABCG2 expressed in baculovirus infected Sf9 cell membrane assessed as decrease in inorganic phosphate production at 1 uM after 20 mins by colorimetry2016European journal of medicinal chemistry, Jul-19, Volume: 117The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID1268166Volume of distribution at steady state in Sprague-Dawley rat at 2 mg/kg, iv2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
AID1356688Intrinsic cytotoxicity in MDCK2 cells overexpressing BCRP assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
AID1167194Inhibition of ABCG2 (unknown origin) expressed in HEK293 cells assessed as reduction in mitoxantrone efflux after 30 mins by FACS method2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
AID1326800Inhibition of ABCG2 (unknown origin) expressed in HEK293 cells assessed as reduction in mitoxantrone efflux at 1 uM after 30 mins by flow cytometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
AID1479726Cytotoxicity against MDCK2 cells assessed as decrease in cell viability after 72 hrs by MTT assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold.
AID1525951Inhibition of BCRP (unknown origin)2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1303187Inhibition of human C-terminal GFP-tagged ABCG2 expressed in MDCK2 cells using pheophorbide A as substrate preincubated for 20 mins followed by substrate addition measured after 120 mins by flow cytometry2016European journal of medicinal chemistry, Jul-19, Volume: 117The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID1904129Cytotoxicity against dog MDCK-II-BCRP cells after 48 hrs by MTT assay2022European journal of medicinal chemistry, Apr-05, Volume: 233Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
AID578760Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID1690380Activation of ABCB1 ATPase activity (unknown origin) expressed in baculovirus infected Sf9 insect cells using ATP as substrate measured after 1 hr by colorimetric assay relative to sulfasalazine2020European journal of medicinal chemistry, Apr-01, Volume: 191Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).
AID1832470Chemo-sensitizing activity against mitoxantrone-selected ABCG2-overexpressing human NCI-H460/MX20 cells assessed as reversal fold at 1 uM measured after 72 hrs in presence of mitoxantrone by CCK8 assay relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Sophoraflavanone G Resensitizes ABCG2-Overexpressing Multidrug-Resistant Non-Small-Cell Lung Cancer Cells to Chemotherapeutic Drugs.
AID1347054Inhibition of BCRP-mediated mitoxantrone efflux in human myeloid leukemia PLB985 cells measured by flow cytometry2017SLAS discovery : advancing life sciences R & D, 01, Volume: 22, Issue:1
Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (9.80)29.6817
2010's36 (70.59)24.3611
2020's10 (19.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.18 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index35.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.96%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other50 (98.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]